Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Evaxion A/S (NASDAQ:EVAX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
Profitability
This table compares Black Diamond Therapeutics and Evaxion A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
| Evaxion A/S | N/A | -61.43% | -34.23% |
Earnings and Valuation
This table compares Black Diamond Therapeutics and Evaxion A/S”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | $70.00 million | 1.62 | $22.37 million | ($0.75) | -2.63 |
| Evaxion A/S | $7.53 million | 3.37 | -$7.71 million | ($1.21) | -2.51 |
Black Diamond Therapeutics has higher revenue and earnings than Evaxion A/S. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and price targets for Black Diamond Therapeutics and Evaxion A/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 1 | 2 | 8 | 0 | 2.64 |
| Evaxion A/S | 1 | 0 | 5 | 0 | 2.67 |
Black Diamond Therapeutics presently has a consensus target price of $10.25, suggesting a potential upside of 420.30%. Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 261.84%. Given Black Diamond Therapeutics’ higher possible upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Evaxion A/S.
Risk & Volatility
Black Diamond Therapeutics has a beta of 3.31, meaning that its share price is 231% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats Evaxion A/S on 9 of the 13 factors compared between the two stocks.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
